Search for a trial

Feasibility Study of the PneumRx, Inc. Lung Volume Reduction Coil for the Treatment of Emphysema

To evaluate the safety and effecacy of the Lung Volume Reduction Coil to improve QOL pulmonary function for emphysema subjects with severe hyperinflation.

Evaluation of the PneumRx, Inc. Lung Volume Reduction Device for the Treatment of Subjects with Homogeneous Emphysema

To evaluate the mechanism of action and effecacy of the Lung Volume Reduction Coil to improve QOL pulmonary function for homogeneous emphysema subjects with severe hyperinflation.

EVALUATION OF THE EFFICACY AND SAFETY OF 6 REPEATED DAILY
DOSES OF NEBULISED RPL554 0.018 mg/kg (6X)
IN ALLERGIC ASTHMATICS

To investigate the efficacy of repeated daily doses of nebulised RPL554 (0.018 mg/kg) by assessing the effect on FEV1 at day 1, 3 and 6 after daily inhaled doses of nebulised RPL554 0.018 mg/kg (6X) in 16 allergic asthmatics.

A phase II open label, roll over study of the long term tolerability, safety and efficacy of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis

to offer continuation of BIBF 1020 treatment for patients with IPF who have completed a prior clinical trial with that drug.establish the long term tolerability and safety profile of BIBF 1120 in IPF.

A Study of the Use of Chartis* System to Optimize Subject Selection for Endobronchial Lung Volume Reduction (ELVR) in Subjects with Heterogeneous Emphysema

To evaluate the effectiveness of the Chartis System in selecting subjects with heterogeneous emphysema who will achieve Lung Volume Reduction from Endobronchial Valve therapy.

A Non-randomized Study to Evaluate the Safety and Performance of the Portaero Pneumostoma System in Patients with Severe Emphysema and Hyperinflation of the Lung

The objective of this study is to evaluate the safety and device performance of the Portaero Pneumostoma System to create and maintain a transthoracic pneumostoma in patients with severe emphysema and hyperinflation.

A Prospective Study of RejuvenAir* System Radial Spray Cryotherapy to Determine Safety and Histological Effect in the Lung

The study objective is to demonstrate the feasibility and safety (measured by the occurrence of serious adverse events) of the RejuvenAir System Radial Spray Cryotherapy in a population of subjects who are scheduled to undergo a planned lobectomy or…

The effect of inhaled heparin on pulmonary coagulation activation and vascular permeability in mechanically ventilated patients with acute lung injury / acute respiratory disress syndrome

Objectives1. to determine whether nebulization of heparin decreases coagulation activation in the pulmonary compartment (i.e. BAL fluid)2. to determine whether nebulization of heparin decreases pulmonary vascular permeability

A Phase 2 Trial of Single-Agent Amrubicin in Patients with Extensive Disease Small Cell Lung Cancer that is Refractory or Progressive within 90 Days of Completion of First Line Platinum-based Chemotherapy

The primary objective is the Objective tumor response rate (RECIST). Secondary objectives are: duration of overall response, time to tumor progression (TTP), progression free survival (PFS), overall survival, toxicity profile, incidence of…

Randomized phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC (ES).

Investigate the activity and safety of amrubicin alone versus amrubicin incombination with cisplatin versus standard treatment for extensive disease(ED) small-cell lung cancer in the first line setting.

A feasibility and safety study of bronchoscopic intrabullous autologous blood instillation for the treatment of severe bullous emphysema.

To assess the safety and effects of bronchoscopic intrabullous blood instillation in patients with bullous emphysema on lung function, quality of life measures, functional measures and CT measured lung volumes.

Phase 2, randomized, controlled, open label multi-center study to assess efficacy and safety of DFV890 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function

The purpose of this study is to evaluate the efficacy and safety of DFV890 in addition to current standard of care (SoC) compared with SoC alone in controlling the inflammatory syndrome and resultant acute respiratory distress syndrome (ARDS) in…

Treatment of central sleep apnoea and Cheyne Stokes respiration in patients with heart failure:
nasal high-flow oxygen therapy?

The aim of the present pilot study is to investigate whether nHFT of different settings (with different flow rates and additional amounts of oxygen) stabilizes respiration and thus improves AHI index and promotes compliance with the therapy in…

A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis (ATLAS Study)

The primary objective is to evaluate safety and tolerability of treatment with AP01.This study will also evaluate the effect of AP01 on various efficacy measures as follows:* To evaluate the safety and tolerability of treatment with AP01 when given…

An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer

The objectives and relevant endpoints of the study are as follows:Primary: To assess the safety and tolerability of ATL001 as amonotherapy and in combination with pembrolizumabSecondary: To evaluate the clinical efficacy of ATL001treatment as a…

Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis

This study has been transitioned to CTIS with ID 2024-515964-30-00 check the CTIS register for the current data. • Allow patients to continue or start AP01 therapy for the treatment of ILD and IPF prior to regulatory approval or until the study is…